GT Medical Technologies Inc. (GT MedTech) has crafted a strategic distribution partnership with Theragenics Corporation that aims to expand physician access to Cesium-131 seeds, thereby providing greater flexibility to support their brachytherapy procedural needs.

GT Medical Technologies Inc.（GT MedTech）与Theragenics Corporation建立了战略分销伙伴关系，旨在扩大医生获得铯-131种子的机会，从而提供更大的灵活性来支持他们的近距离放射治疗程序需求。

'We are very pleased to align with Theragenics, a global brachytherapy leader, to propel the field of cancer care forward.' GT Medical Technologies CEO Per Langoe said. 'This partnership ensures continued access to Cesium-131 for clinicians and patients, addressing critical healthcare needs.'

“我们很高兴与全球近距离放射治疗领导者Theragenics合作，推动癌症护理领域的发展。”GT Medical Technologies首席执行官佩尔·兰戈（PerLangoe）说这种伙伴关系确保临床医生和患者继续获得铯-131，满足关键的医疗保健需求。”

Through the partnership, Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers used for various non-brain cancer related treatments including prostate cancer. GT MedTech, the sole manufacturer of Cesium-131, will continue to focus on expanding adoption of the company's U.S.

通过合作关系，Theragenics将成为铯-131近距离放射治疗种子和载体的独家经销商，用于各种非脑癌相关治疗，包括前列腺癌。GT MedTech是铯-131的唯一制造商，将继续专注于扩大该公司在美国的应用。

Food and Drug Administration (FDA)-cleared GammaTile therapy for treating operable brain tumors in the United States..

美国食品和药物管理局（FDA）批准GammaTile疗法用于治疗美国可手术的脑肿瘤。。

Cesium-131 is a common isotope used with low dose rate [LDR] brachytherapy, a radiation treatment where tiny radioactive seeds are implanted directly into or adjacent to a tumor. This approach delivers a high radiation dose to cancer cells while minimizing damage to surrounding healthy tissues.

铯-131是一种常见的同位素，用于低剂量率（LDR）近距离放射治疗，一种将微小放射性种子直接植入肿瘤或邻近肿瘤的放射治疗方法。这种方法向癌细胞提供高辐射剂量，同时最大限度地减少对周围健康组织的损害。

'This partnership reinforces Theragenics' unwavering commitment to brachytherapy,' Theragenics Interventional President Michael Krachon stated. 'With the addition of Cesium-131 to our portfolio, we can more comprehensively support the clinical needs of the brachytherapy community and further expand our efforts to raise awareness of brachytherapy as a viable treatment option for men battling prostate cancer.'.

Theragenics介入总裁迈克尔·克拉克森（MichaelKrachon）表示，这种合作关系加强了Theragenics对近距离放射治疗的坚定承诺随着铯-131加入到我们的投资组合中，我们可以更全面地支持近距离放射治疗社区的临床需求，并进一步扩大我们的努力，以提高对近距离放射治疗作为治疗前列腺癌男性可行治疗选择的认识。

As the exclusive manufacturer of Cesium-131, GT MedTech is dedicated to expanding its utilization to advance cancer care. Concurrently, GT MedTech is focused on driving the evidence-based adoption of GammaTile, aiming to establish a new standard of care for operable brain tumors.*

作为铯-131的独家制造商，GT MedTech致力于扩大其利用率以促进癌症治疗。与此同时，GT MedTech专注于推动GammaTile的循证采用，旨在为可手术的脑肿瘤建立新的护理标准*

Driven to raise the standard of care, a team of brain tumor specialists formed GT Medical Technologies. GammaTile is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 100 institutions. .

为了提高护理标准，一组脑肿瘤专家成立了GT医疗技术公司。GammaTile被FDA批准用于治疗新诊断的恶性颅内肿瘤患者和复发性颅内肿瘤患者。自2020年3月在美国全面上市以来，GammaTile已在100多家机构推出。。

Theragenics is a pioneer in brachytherapy, offering minimally invasive, radiation-based treatments for prostate and other cancers. Through its subsidiaries, the company designs and delivers a portfolio of vascular access, specialty needles products, and surgical devices, serving critical needs across interventional radiology, interventional cardiology, and vascular surgery.  .

Theragenics是近距离放射治疗的先驱，为前列腺癌和其他癌症提供微创放射治疗。通过其子公司，该公司设计并提供血管通路、专用针头产品和手术设备的组合，满足介入放射学、介入心脏病学和血管外科的关键需求。。